Management of prostate cancer in elderly men

Seminars in Radiation Oncology

Volumn 23, Issue 3, 2013, Pages 198-205

  Bian, Shelly X ^a   Hoffman, Karen E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BRACHYTHERAPY; CANCER MORTALITY; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER THERAPY; CARDIOVASCULAR MORTALITY; CONSERVATIVE TREATMENT; DIGITAL RECTAL EXAMINATION; ENTERITIS; ERECTILE DYSFUNCTION; EXHAUSTION; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL STATUS; GAIT DISORDER; GASTROINTESTINAL DISEASE; GERIATRIC DISORDER; HUMAN; LIFE EXPECTANCY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION INJURY; REVIEW; SEXUAL FUNCTION; SIDE EFFECT; SOCIAL SECURITY; SURGICAL MORTALITY; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; WEAKNESS; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; HEALTH SERVICES FOR THE AGED; HUMANS; MALE; PATIENT CARE MANAGEMENT; PROSTATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 84878884716     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.01.007     Document Type: Review

References (63)

1. Projections of the population by age and sex for the United States: 2010 to 2050 (NP2008-T12). Washington, DC, U.S. Census Bureau, Statistical Abstract of the United States: 2012, Population Division, 2011.
2. NCCN clinical practice guidelines in oncology. Prostate Cancer. V.3.2012. National Comprehensive Cancer Network Accessed June 27, 2012. http://www.nccn.org.
3. Walter L.C., Covinsky K.E. Cancer screening in elderly patients: A framework for individualized decision making. JAMA 2001, 285:2750-2756.
4. Jeldres C., Latouff J.B., Saad F. Predicting life expectancy in prostate cancer patients. Curr Opin Support Palliat Care 2009, 3:166-169.
5. Levine G.N., D'Amico A.V., Berger P., et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. Circulation 2010, 121:833-840.
6. Cowen M.E., Halasyamani L.K., Kattan M.W. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 2006, 175:99-103.
7. Tewari A., Johnson C.C., Divine G., et al. Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004, 171:1513-1519.
8. Albertsen P.C., Fryback D.G., Storer B.E., et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996, 156:127-132.
9. Walz J., Gallina A., Saad F., et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007, 25:3576-3581.
10. Dall'Era M.A., Konety B.R., Cowan J.E., et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008, 112:2664-2670.
11. Tosoian J.J., Trock B.J., Landis P., et al. Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J Clin Oncol 2011, 29:2185-2190.
12. Klotz L., Zhang L., Lam A., et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126-131.
13. Lu-Yao G.L., Albertsen P.C., Moore D.F., et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009, 302:1202-1209.
14. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977-1984.
15. Cooperberg M.R., Lubeck D.P., Meng M.V., et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004, 22:2141-2149.
16. Roberts C.B., Albertsen P.C., Shao Y.H., et al. Patterns and correlates of prostate cancer treatment in older men. Am J Med 2011, 124:235-243.
17. Daskivich T.J., Chamie K., Kwan L., et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011, 117:2058-2066.
18. Albertsen P.C., Fryback D.G., Storer B.E., et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995, 274:626-631.
19. Bechis S.K., Carroll P.R., Cooperberg M.R. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011, 29:235-241.
20. Schwartz K.L., Alibhai S.M., Tomlinson G., et al. Continued undertreatment of older men with localized prostate cancer. Urology 2003, 62:860-865.
21. Alibhai S.M., Naglie G., Nam R., et al. Do older men benefit from curative therapy of localized prostate cancer?. J Clin Oncol 2003, 21:3318-3327.
22. Wong Y.N., Mitra N., Hudes G., et al. 2006: Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006, 296:2683-2693.
23. Nguyen P.L., Chen M.H., Renshaw A.A., et al. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations. Int J Radiat Oncol Biol Phys 2010, 76:337-341.
24. Hoffman K.E., Chen M.H., Moran B.J., et al. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer 2010, 116:2590-2595.
25. Walz J., Montorsi F., Jeldres C., et al. The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: a population-based analysis of 9208 consecutive cases. BJU Int 2008, 101:826-832.
26. Alibhai S.M., Leach M., Tomlinson G., et al. 30-Day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005, 97:1525-1532.
27. Kundu S.D., Roehl K.A., Eggener S.E., et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004, 172:2227-2231.
28. Stanford J.L., Feng Z., Hamilton A.S., et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA 2000, 283:354-360.
29. Mohamad B.A., Marszalek M., Brössner C., et al. Radical prostatectomy in Austria: a nationwide analysis of 16,524 cases. Eur Urol 2007, 51:684-688. discussion 689.
30. Jani A.B., Parikh S.D., Vijayakumar S., et al. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer. Urology 2005, 65:1157-1162.
31. Geinitz H., Zimmermann F.B., Thamm R., et al. 3D conformal radiation therapy for prostate cancer in elderly patients. Radiother Oncol 2005, 76:27-34.
32. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 2000, 47:103-113.
33. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
34. Budäus L., Bolla M., Bossi A., et al. Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature. Eur Urol 2012, 61:112-127.
35. Pinkawa M., Gagel B., Piroth M.D., et al. Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 2009, 55:227-234.
36. Alemozaffar M., Regan M.M., Cooperberg M.R., et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011, 306:1205-1214.
37. Chen A.B., D'Amico A.V., Neville B.A., et al. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 2006, 24:5298-5304.
38. Hu J.C., Elkin E.P., Pasta D.J., et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol 2004, 171:703-707. discussion 707-708.
39. Daskivich T.J., van de Poll-Franse L.V., Kwan L., et al. From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer. Prostate Cancer Prostatic Dis 2010, 13:320-327.
40. Bolla M., Van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073.
41. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008, 299:289-295.
42. Denham J.W., Steigler A., Lamb D.S., et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011, 12:451-459.
43. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
44. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
45. Denham J.W., Steigler A., Lamb D.S., et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011, 12:451-459.
46. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
47. Nguyen P.L., Chen M.H., Beard C.J., et al. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: A postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys 2010, 77:1046-1052.
48. D'Amico A.V., Chen M.H., Renshaw A.A., et al. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys 2009, 75:10-15.
49. Bian S.X., Kuban D.A., Levy L.B., et al. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol 2012, 23:2346-2352.
50. Bian SX, Kuban DA, Levy LB, et al: The Addition of Short-term Androgen Deprivation Therapy to Dose-Escalated Radiation Therapy Improves Failure-Free Survival For Older Men With Intermediate-Risk Prostate Cancer American Society for Radiation Oncology Annual Meeting, Abstract 1046, Boston, MA, October 29-31, 2012; 2012.
51. RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer Accessed October 1, 2012. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0815.
52. Konety B.R., Cowan J.E., Carroll P.R., et al. Patterns of primary and secondary therapy for prostate cancer in elderly men: Analysis of data from CaPSURE. J Urol 2008, 179:1797-1803. discussion 1803.
53. Smith M.R., Lee W.C., Brandman J., et al. Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005, 23:7897-7903.
54. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4456.
55. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25:2420-2425.
56. Nguyen P.L., Je Y., Schutz F.A., et al. 2011: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials. Jama 2011, 306:2359-2366.
57. Nanda A., Chen M.H., Braccioforte M.H., et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. Jama 2009, 302:866-873.
58. Nguyen P.L., Chen M.H., Beckman J.A., et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 2012, 82:1411-1416.
59. Bylow K., Mohile S.G., Stadler W.M., et al. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: A conceptual review. Cancer 2007, 110:2604-2613.
60. Wilke D.R., Parker C., Andonowski A., et al. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists. BJU Int 2006, 97:963-968.
61. Howlader N., Noone A.M., Krapcho M., et al. SEER Cancer Statistics Review, pp 1975-2008 Bethesda, MD, National Cancer Institute, based on 2010 SEER data submission, posted to the SEER web site, 2011. Accessed October 1, 2012. http://seer.cancer.gov/csr/1975_2008/.
62. Shao Y.H., Demissie K., Shih W., et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009, 101:1280-1283.
63. Period life table, 2007 Social Security Administration, Accessed December 1, 2011. http://www.ssa.gov/oact/STATS/table4c6.html.